Latest News about EDIT
Recent news which mentions EDIT
Ocugen Stock: Bull vs. Bear
November 20, 2021
From Motley Fool
Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript
November 08, 2021
Tickers
EDIT
From Motley Fool
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
From Benzinga
Should You Scoop Up Shares of This Promising Biotech on the Dip?
October 28, 2021
Tickers
EDIT
From Motley Fool
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
October 21, 2021
From Benzinga
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
October 19, 2021
From Benzinga
2 Tricks and a Treat for Gene Therapy Investors
October 18, 2021
From Motley Fool
From Motley Fool
What's Hot in the Stock Market?
October 11, 2021
From Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
October 08, 2021
From Benzinga
3 Spooky Healthcare Stocks I Would Avoid in October
October 07, 2021
From Motley Fool
52 Biggest Movers From Yesterday
September 30, 2021
From Benzinga
4 Top Stock Trades for Thursday: LCID, DKNG, DLTR, EDIT
September 29, 2021
From InvestorPlace
LSPD Stock: Why This Analyst Report Predicts Up to 80% Downside for Lightspeed Commerce
September 29, 2021
From InvestorPlace
EDIT Stock Is Plunging 20%. Here’s the Gene-Editing News Dragging It Down.
September 29, 2021
Tickers
EDIT
From InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
September 29, 2021
From Benzinga
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate
September 29, 2021
Tickers
EDIT
From Benzinga
Why Shares of Editas Medicine Are Lower This Morning
September 29, 2021
From Motley Fool
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
September 29, 2021
From Benzinga
Breaking Down CRISPR Technology
September 28, 2021
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
September 24, 2021
From Benzinga
Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another
September 23, 2021
From Motley Fool
Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years
September 23, 2021
From Motley Fool
3 Moonshot Stocks Hidden in Cathie Wood’s Portfolios
September 22, 2021
From InvestorPlace
7 Gene Editing Stocks Promising to Change our DNA
September 15, 2021
From InvestorPlace